Overview
Compare with BONK, INC., DSwiss Inc or COSCIENS Biopharma Inc., or pick any stock.
- TickerSHFH on OTC1
- IndustryPerfumes, Cosmetics & Other Toilet Preparations1
- HeadquartersKwun Tong, Hong Kong1
- Incorporated inNV3
- Business address3/F, Mow Hing Industrial Building, 205 Wai Yip Street, Kwun Tong, K3 000003
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
See how the biggest companies compare on our leaderboards
Scientist Home Future Health Limited (“we”, “us”, “our”, or the “Company”), was incorporated on July 3, 2024 in the State of Nevada.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Scientist Home Mixed Gelatine Hydrolysate brought in 31% of the revenue Scientist Home Future Health Ltd broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2025 |
|---|---|
| Scientist Home Mixed Gelatine Hydrolysate | $60.5K |
| Others (Delivery Fee) | $47.8K |
| Scientist Home High Concentration Proteinase | $43.8K |
| Scientist Home Vein Cream | $22.6K |
| Scientist Home Cholipolysis Cholic Acid | $13.4K |
| Scientist Home Bone Gelatine Hydrolysate | $9.4K |
Business segments
Retail Trading Business brought in 97% of the revenue Scientist Home Future Health Ltd broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2025 |
|---|---|
| Retail Trading Business | $197.4K |
| Service Business | $6.6K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue28¢$122.2K
- Selling, general and admin72¢$313.6K
Out of $197.4K in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 1 fiscal year, latest first.2
| Period ending | 2025-12-31 |
|---|---|
| Retail trading revenue | $197.4K |
| Service revenue | $6.6K |
| Cost of retail trading revenue: (including $121,075 & $67,865 of cost of retail trading revenue to related party for the year ended December 31, 2025 and the period ended December 31, 2024) | -$121.1K |
| Cost of service revenue | -$1.1K |
| Gross profit | $81.9K |
| Selling, general and administrative expenses (including $19,242 & 7,692 of selling, general and administrative expenses to related party for the year ended December 31, 2025 and the period ended December 31, 2024) | -$313.6K |
| (Loss) from operation | -$231.7K |
| Other Income | $0 |
| (Loss) before income tax | -$231.7K |
| Income tax benefit/(provision) | $0 |
| Net (loss) | -$231.7K |
| Foreign currency translation | -$2.9K |
| Total Comprehensive (Loss) | -$234.6K |
| Net (loss) per share, basic and diluted | -$0.01 |
| Weighted average number of common shares outstanding - Basic and diluted | 23.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $68.9K | $18.6K | $0 |
| Inventories | $34.0K | $2.6K | |
| Deposits and prepayments | $89.4K | $0 | |
| Total current assets | $192.2K | $21.2K | |
| Right-of-use assets, net (including $33,435 of right-of-use assets from related party as of December 31, 2025) | $378.9K | $0 | |
| Property, plant and equipment, net | $73.2K | $0 | |
| Total non-current assets | $452.1K | $0 | |
| Total assets | $644.4K | $21.2K | |
| Other payables and accrued liabilities | $44.6K | $15.0K | |
| Income tax payable | $1.8K | $1.8K | |
| Amount due to a related party | $78.3K | $4.2K | |
| Amount due to a director | $15.6K | $6.2K | |
| Lease liability - current portion (including $21,997 of lease liability - current portion to related party as of December 31, 2025) | $74.2K | $0 | |
| Total current liabilities | $214.5K | $27.3K | |
| Lease liability - non-current portion (including $11,438 lease liability - non-current portion to related party as of December 31, 2025) | $316.5K | $0 | |
| Total non-current liabilities | $316.5K | $0 | |
| Total liabilities | $531.0K | $27.3K | |
| Common stock, par value $0.0001; 200,000,000 shares authorized, 23,716,000 and 23,480,000 issued and outstanding as of December 31, 2025 and 2024, respectively | $2.4K | $2.3K | |
| Additional paid in capital | $360.6K | $6.6K | |
| Accumulated other comprehensive income | -$2.9K | $0 | |
| Accumulated deficit | -$246.7K | -$15.0K | |
| Total stockholders' equity | $113.4K | -$6.0K | $10 |
| Total liabilities and stockholders' equity | $644.4K | $21.2K | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 23.7M shares | 23.5M shares | |
| Common stock, shares outstanding | 23.7M shares | 23.5M shares | |
| Lease liability - current portion to related party | $22.0K | ||
| Lease liability - non-current portion to related party | $11.4K | ||
| Right-of-use assets | $33.4K |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $68.9K | $18.6K | $0 |
| Inventories | $34.0K | $2.6K | |
| Deposits and prepayments | $89.4K | $0 | |
| Total current assets | $192.2K | $21.2K | |
| Right-of-use assets, net (including $33,435 of right-of-use assets from related party as of December 31, 2025) | $378.9K | $0 | |
| Property, plant and equipment, net | $73.2K | $0 | |
| Total non-current assets | $452.1K | $0 | |
| Total assets | $644.4K | $21.2K | |
| Other payables and accrued liabilities | $44.6K | $15.0K | |
| Income tax payable | $1.8K | $1.8K | |
| Amount due to a related party | $78.3K | $4.2K | |
| Amount due to a director | $15.6K | $6.2K | |
| Lease liability - current portion (including $21,997 of lease liability - current portion to related party as of December 31, 2025) | $74.2K | $0 | |
| Total current liabilities | $214.5K | $27.3K | |
| Lease liability - non-current portion (including $11,438 lease liability - non-current portion to related party as of December 31, 2025) | $316.5K | $0 | |
| Total non-current liabilities | $316.5K | $0 | |
| Total liabilities | $531.0K | $27.3K | |
| Common stock, par value $0.0001; 200,000,000 shares authorized, 23,716,000 and 23,480,000 issued and outstanding as of December 31, 2025 and 2024, respectively | $2.4K | $2.3K | |
| Additional paid in capital | $360.6K | $6.6K | |
| Accumulated other comprehensive income | -$2.9K | $0 | |
| Accumulated deficit | -$246.7K | -$15.0K | |
| Total stockholders' equity | $113.4K | -$6.0K | $10 |
| Total liabilities and stockholders' equity | $644.4K | $21.2K | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 23.7M shares | 23.5M shares | |
| Common stock, shares outstanding | 23.7M shares | 23.5M shares | |
| Lease liability - current portion to related party | $22.0K | ||
| Lease liability - non-current portion to related party | $11.4K | ||
| Right-of-use assets | $33.4K |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 1 fiscal year, latest first.2
| Period ending | 2025-12-31 |
|---|---|
| Net (loss) | -$231.7K |
| Depreciation | $1.7K |
| Amortization of operating lease right-of-use assets | $24.8K |
| Inventories | -$31.3K |
| Deposits and prepayments | -$89.2K |
| Other payables and accrued liabilities | $29.6K |
| Amount due to a related party | $61.0K |
| Income tax payable | $0 |
| Change in lease liability | -$13.1K |
| Total changes in operating assets and liabilities | -$16.6K |
| Net cash used in operating activities | -$248.3K |
| Purchase of property, plant and equipment | -$74.8K |
| Net cash used in investing activity | -$74.8K |
| Issuance of shares | $354.0K |
| Amount due to a related party | $12.8K |
| Amount due to a director | $9.3K |
| Net cash provided by financing activities | $376.1K |
| Effect of exchange rate changes in cash and cash equivalents | -$2.8K |
| Net increase in cash and cash equivalents | $50.3K |
| Income taxes paid | $0 |
| Interest paid | $0 |
| Initial recognition of operating lease right-of-use assets and operating lease obligations upon adoption of ASC Topic 842 | $403.8K |
| Initial recognition of the balance payment of finance lease right-of-use asset by finance lease liabilities | $0 |
No quarter-by-quarter statement was filed.
Compare Scientist Home Future Health Ltd with another company
What it owns
What Scientist Home Future Health Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $74.9K2 Dec 31, 2025 | $02 Dec 31, 2024 | |
| Accumulated depreciation | $1.7K2 Dec 31, 2025 | $02 Dec 31, 2024 | |
| Property and equipment, net | $73.2K2 Dec 31, 2025 | $02 Dec 31, 2024 | |
| Operating-lease assets (leased space) | $378.9K2 Dec 31, 2025 | $02 Dec 31, 2024 |
Inventory
Properties, in its own words
We currently lease two physical offices in Hong Kong.
Our office is located at Room B3, Block B, 3/F, Mow Hing Industrial Building, 205 Wai Yip Street, Kwun Tong, Kowloon, Hong Kong. The Company has entered a new lease for a lease term of 24 months or less, commence from July 1, 2025. The monthly rental cost for this office space is approximately $1,924 (HK$15,000). The lease will end on June 30, 2027. The lease does not have any renewal option.
The rest of Item 2
Another office is located at Unit No. 11, 2/F, Wing On Plaza, No. 62 Mody Road, Kowloon, Hong Kong. The Company has entered a new lease for a lease term of 36 months or less, commence from September 16, 2025. The monthly rental cost for this office space is approximately $5,773 (HK$45,000). The lease will end on September 15, 2028. The lease has a renewal option for the period from September 16, 2028 to September 15, 2031, with 4% annual increment on monthly rental cost per year.
Item 2 of the 10-K filed Mar 27, 2026.4
Filings
17 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 11 other. The latest 17:
- Aug 11, 202610-Q EDGAR
- May 14, 202610-Q EDGAR
- Mar 27, 202610-K EDGAR
- Nov 12, 202510-Q EDGAR
- Aug 12, 202510-Q EDGAR
- May 15, 202510-Q EDGAR
- Apr 28, 2025EFFECT EDGAR
- Apr 24, 2025CORRESP EDGAR
- Apr 16, 2025S-1/A EDGAR
- Mar 27, 2025S-1/A EDGAR
- Mar 20, 2025UPLOAD EDGAR
- Mar 6, 2025S-1/A EDGAR
- Jan 31, 2025UPLOAD EDGAR
- Jan 16, 2025S-1/A EDGAR
- Dec 23, 2024UPLOAD EDGAR
- Nov 25, 2024S-1/A EDGAR
- Nov 25, 2024S-1 EDGAR
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How Scientist Home Future Health Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARScientist Home Future Health Ltd1
- CIK0002032609
- Employer ID (EIN)30-14166364
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inNevada4
- Fiscal year endsDecember 311
- Industry code (SIC)2844 Perfumes, Cosmetics & Other Toilet Preparations1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address3/F, Mow Hing Industrial Building, 205 Wai Yip Street, Kwun Tong, K3 000001
- Phone852570230761
- Shares outstanding23,716,000 as of Jun 30, 20265
- Public float$0 as of Jun 30, 20252
- AuditorJP CENTURION & PARTNERS PLT, Kuala Lumpur, Malaysia PCAOB ID 6723; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceNov 25, 20241
- Filings17 in all: 10-Q (5), S-1/A (5), UPLOAD (3), 10-K (1), CORRESP (1), EFFECT (1), S-1 (1)1
- Latest filingsAnnual report (10-K) Mar 27, 2026
Quarterly report (10-Q) Aug 11, 2026
Risk factors and legal proceedings
Legal proceedings
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8